'Challenged road ahead as Novo attempts to return to its former glory': Seigerman – BNN Bloomberg

Skip to main content

ADVERTISEMENT

The Close

'Challenged road ahead as Novo attempts to return to its former glory': Seigerman

Evan Seigerman, managing director and head of healthcare research at BMO Capital Markets, joins BNN Bloomberg to discuss the FDA's approval of Wegovy weight loss pill from Novo Nordisk.

December 23, 2025 at 4:38PM EST

Cost pressures threaten grocery access in remote areasOpens in new window

06:30 · May 22, 2026 at 4:50PM EDT

Will fundamentals keep up with AI hype?Opens in new window

06:39 · May 22, 2026 at 4:48PM EDT

Trump postpones executive order for AI oversightOpens in new window

06:13 · May 21, 2026 at 4:54PM EDT

'It's less about oil and more about interest rates': Ablin on market's threshold for oilOpens in new window

07:04 · May 21, 2026 at 4:53PM EDT

U.S. stocks rally as oil prices retreatOpens in new window

06:17 · May 21, 2026 at 4:14PM EDT

Nvidia losing share as rivals sign deals: SeaportOpens in new window

09:26 · May 20, 2026 at 4:45PM EDT

Will higher mortgage rates weigh on home sales?Opens in new window

06:22 · May 20, 2026 at 4:17PM EDT

'We got to get this dealt with in the next couple of weeks': Pelletier on Iran war and oil shortagesOpens in new window

07:21 · May 20, 2026 at 4:06PM EDT

What to watch in U.S. retail earningsOpens in new window

07:18 · May 19, 2026 at 4:42PM EDT

Food inflation sees slight cooling in AprilOpens in new window

07:30 · May 19, 2026 at 4:41PM EDT